Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLNR | O43193 | 1/20 | 0.51 |
| ▸ | SCD | O00767 | 6/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
| ▸ | GPR6 | P46095 | 2/20 | 0.42 |
| ▸ | FPR2 | P25090 | 1/20 | 0.41 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.41 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2009322 | 0.84 | MLNR (0.50) | MLNRSCDHRH3MALT1 | |
| SCHEMBL2006866 | 0.78 | MLNR (0.52) | MLNRSCDMALT1 | |
| SCHEMBL2009209 | 0.78 | KDM4E (0.48) | MLNRSCDHRH3MALT1 | |
| SCHEMBL29002493 | 0.75 | GPR6 (0.50) | GPR6CYP2D6 | |
| SCHEMBL27703256 | 0.74 | MALT1 (0.51) | HRH3MALT1 | |
| SCHEMBL2008677 | 0.72 | MALT1 (0.46) | MALT1 | |
| SCHEMBL3832526 | 0.72 | SCD (0.47) | SCDFPR2PROKR1 | |
| SCHEMBL12093608 | 0.72 | HRH3 (0.57) | MLNRHRH3 | |
| SCHEMBL2011532 | 0.71 | MLNR (0.50) | MLNRMALT1CYP2D6 | |
| SCHEMBL29966 | 0.71 | SLC6A2 (0.61) | FPR2PROKR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7964602-B2 | Biaryl compounds useful as agonists of the Gpr38 receptor | GLAXO GROUP LIMITED (GB) | 2011-06-21 | — | — | US | disclosed |
| EP-1960390-B1 | BIARYL COMPOUNDS USEFUL AS AGONISTS OF THE GPR38 RECEPTOR | GLAXO GROUP LTD (GB) | 2010-07-21 | — | — | EP | disclosed |
| US-20080306083-A1 | Biaryl Compounds Useful as Agonists of the Gpr38 Receptor | GLAXO GROUP LIMITED | 2008-12-11 | — | — | US | disclosed |
| EP-1960390-A1 | BIARYL COMPOUNDS USEFUL AS AGONISTS OF THE GPR38 RECEPTOR | GLAXO GROUP LIMITED (GB) | 2008-08-27 | — | — | EP | disclosed |
| WO-2007065669-A1 | BIARYL COMPOUNDS USEFUL AS AGONISTS OF THE GPR38 RECEPTOR | GLAXO GROUP LIMITED (GB) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306083-A1 | Biaryl Compounds Useful as Agonists of the Gpr38 Receptor | GPR88, GPR68, GPBAR1 | MLNR 47/4885SCD 704/4885HRH3 320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.